GBTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (5 10月 2022 @ 05:00):

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD)...

Stats
本日の出来高	3.28M
平均出来高	0
時価総額	0.00
EPS	$0 ( 2022-11-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.08
ATR14	$0.890 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2022-10-05	Perry Mark L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Patrick Deval L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Morrison Scott W	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Thompson Alexis A.	Sell	3 600	Restricted Stock Units
2022-10-05	Yarno Wendy L	Sell	30 000	Stock Option (Right to Buy)

INSIDER POWER
-60.36
Last 100 transactions
Buy: 278 284 \| Sell: 1 075 911

ボリューム相関

長: 0.35 (neutral)

短: 0.93 (very strong)

Signal:(77.112) Expect same movement, but be aware

Global Blood 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Global Blood 相関 - 通貨/商品

-0.74
( moderate negative )

-0.79
( moderate negative )

0.49
( neutral )

-0.77
( moderate negative )

0.31
( neutral )

0.78
( moderate )

Global Blood 財務諸表

Annual	2021
収益:	$194.75M
総利益:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2021
収益:	$194.75M
総利益:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2020
収益:	$123.80M
総利益:	$121.82M (98.40 %)
EPS:	$-4.04

FY	2019
収益:	$2.11M
総利益:	$2.06M (97.72 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Global Blood

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.